Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Oral Proliferative Verrucous Leukoplakia
NCT03692325Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2018
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in proliferative verrucous leukoplakia (PVL), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Best Overall Response Rate up to 164 days. Started Dec 2018; status: completed.
02
Drugs
03
Conditions
proliferative verrucous leukoplakia (PVL)
Beyond the preview
Go deeper on NCT03692325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03692325.